Maxim analyst Jason McCarthy lowered the firm’s price target on INmune Bio (INMB) to $8 from $30 but keeps a Buy rating on the shares. The firm cites the failure of lead drug XPro to demonstrate clinical improvements in the company’s Phase 2 Alzheimer’s disease trial, but while the top-line data is disappointing, there were some promising aspects and the company continues to develop its pipeline, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INMB:
- INmune Bio downgraded to Underperform from Outperform at Scotiabank
- INmune Bio downgraded to Neutral from Buy at BTIG
- Inmune Bio’s Xpro Alzheimer’s Trial Faces Challenges, Justifying Hold Rating
- Inmune Bio Secures $18.9 Million in Stock Offering
- INmune Bio downgraded to Neutral from Buy at Lucid Capital